Back to top
more

Entrada Therapeutics (TRDA)

(Delayed Data from NSDQ)

$5.30 USD

5.30
498,972

-0.65 (-10.92%)

Updated Aug 7, 2025 04:00 PM ET

After-Market: $5.28 -0.02 (-0.38%) 6:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (100 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of -20.93% and -78.02%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Entrada Therapeutics (TRDA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 46.15% and 111.61%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

by Zacks Equity Research

Eton Pharmaceuticals (ETON) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Entrada Therapeutics (TRDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Ultragenyx (RARE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 104.55% and 173.66%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vir Biotechnology (VIR) delivered earnings and revenue surprises of 10.59% and 15.22%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

by Zacks Equity Research

BLUE and GILD are in the spotlight this week on key updates.

Zacks Equity Research

Here's Why Encompass Health is a Smart Addition to Your Portfolio

by Zacks Equity Research

EHC is well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, frequent expansion initiatives and solid cash reserves.

Zacks Equity Research

Best Momentum Stocks to Buy for December 30th

by Zacks Equity Research

CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.

Zacks Equity Research

New Strong Buy Stocks for December 30th

by Zacks Equity Research

CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.

Zacks Equity Research

Recent Price Trend in Entrada Therapeutics (TRDA) is Your Friend, Here's Why

by Zacks Equity Research

Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Entrada Therapeutics (TRDA) delivered earnings and revenue surprises of 47.76% and 20.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's Why Momentum in Entrada Therapeutics (TRDA) Should Keep going

by Zacks Equity Research

Entrada Therapeutics (TRDA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Zacks Equity Research

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Arvinas (ARVN) delivered earnings and revenue surprises of 22.73% and 45.09%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Here's What Could Help Entrada Therapeutics (TRDA) Maintain Its Recent Price Strength

by Zacks Equity Research

Entrada Therapeutics (TRDA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

by Zacks Equity Research

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

Zacks Equity Research

Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up

by Zacks Equity Research

Lexicon (LXRX) announces a portfolio reprioritization plan to focus on reducing operational expenses and driving the growth of the commercial portfolio. Shares rise.

Zacks Equity Research

Ascendis (ASND) Up on FDA Nod for Hormone Therapy Yorvipath

by Zacks Equity Research

The FDA approves Ascendis' (ASND) Yorvipath (palopegteriparatide) as the first and only treatment for hypoparathyroidism in adult patients. Shares rise.

Zacks Equity Research

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

by Zacks Equity Research

A $75 million performance-based and program-based milestone payment has been triggered in favor of Evotec (EVO) under its strategic collaboration with Bristol Myers for molecular glue degraders.

Zacks Equity Research

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

by Zacks Equity Research

Syros (SYRS) plummets 62% after the decision to discontinue the leukemia study of its investigational candidate, tamibarotene, due to a low likelihood of success per a planned futility analysis.

Zacks Equity Research

FATE Q2 Earnings Beat on Lower Expenses, Collaboration Revenues Grow

by Zacks Equity Research

FATE reports a lower-than-expected loss on higher revenues and lower operating expenses in the second quarter of 2024.

Zacks Equity Research

Here's Why You Should Invest in BioMarin (BMRN) Stock Now

by Zacks Equity Research

Here, we are discussing some reasons why investing in BioMarin (BMRN) stock now may turn out to be a prudent move.